Jiangfu Fuwei granules alleviate chronic atrophic gastritis by suppressing angiogenesis through the PI3K-AKT-HIF1α pathway
American Journal of Translational Research · 2026 · 18 (3) · 2489-2506
DOI: 10.62347/abom6140 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Translational Research, 2026. Verfasst von Yuqing Bi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pi-Wei Disease, The Third Affiliated Hospital of Yunnan University of Chinese Medicine Kunming 650500, Yunnan, China. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
OBJECTIVE: Jiangfu Fuwei granules (JFFW) are a widely used clinical prescription for the treatment of chronic atrophic gastritis (CAG), but the underlying molecular mechanism remains to be explored. This study aimed to elucidate the therapeutic mechanism of JFFW in alleviating CAG. METHODS: experiments were conducted to verify the predicted mechanisms, including histologic evaluation, enzyme-linked immunosorbent assay, and immunohistochemical analysis. Furthermore, molecular docking was used to simulate the interaction between key active compounds and core protein targets. RESULTS: experimental results demonstrated that JFFW effectively reversed gastric mucosal thinning and glandular loss in CAG mice. This treatment significantly restored serum pepsinogen levels and downregulated the expression of inflammatory cytokines, specifically interleukin-6, interleukin-1β, and tumor necrosis factor-α. Network pharmacology analysis identified 224 bioactive compounds and predicted the phosphoinositol 3-kinase (PI3K)-protein kinase B (AKT)-hypoxia-inducible factor 1-α (HIF1α) signaling pathway as a key target. Immunohistochemical results confirmed that JFFW treatment significantly inhibited the protein expression of phosphorylated AKT and HIF1α. Furthermore, reduced CD31 staining occurred consistent with a decrease in microvessel density. Molecular docking analysis further confirmed that the main components of JFFW had a good binding affinity to PI3K protein. CONCLUSION: The therapeutic effect of JFFW on CAG is mainly achieved by inhibiting the PI3K-AKT-HIF1α signaling pathway, thereby suppressing abnormal angiogenesis and gastric inflammation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pi-Wei Disease, The Third Affiliated Hospital of Yunnan University of Chinese Medicine Kunming 650500, Yunnan, China.
- Department of Pi-Wei Disease, The First Affiliated Hospital of Yunnan University of Chinese Medicine Kunming 650021, Yunnan, China.
- Department of Oncology, The First Affiliated Hospital of Kunming Medical University Kunming 650118, Yunnan, China.
Zitieren
APA
Bi, Y., Chen, Y., Jiang, J., Mao, W., Zhang, X., Liu, J., Zhao, X., Dong, Y., Cai, Y., Li, M., Li, X., Luan, Y., & Jiang, L. (2026). Jiangfu Fuwei granules alleviate chronic atrophic gastritis by suppressing angiogenesis through the PI3K-AKT-HIF1α pathway. American Journal of Translational Research, 18(3), 2489-2506. https://doi.org/10.62347/abom6140
Vancouver
Bi Y, Chen Y, Jiang J, Mao W, Zhang X, Liu J, et al. Jiangfu Fuwei granules alleviate chronic atrophic gastritis by suppressing angiogenesis through the PI3K-AKT-HIF1α pathway. American Journal of Translational Research. 2026;18(3):2489-2506. doi:10.62347/abom6140
BibTeX
@article{Bi2026,
author = {Bi, Yuqing and Chen, Yanchun and Jiang, Jimei and Mao, Wangqi and Zhang, Xiao and Liu, Jiayi and Zhao, Xin and Dong, Yueqiu and Cai, Yueqing and Li, Mei and Li, Xiang and Luan, Yunpeng and Jiang, Liyun},
title = {Jiangfu Fuwei granules alleviate chronic atrophic gastritis by suppressing angiogenesis through the PI3K-AKT-HIF1α pathway},
journal = {American Journal of Translational Research},
year = {2026},
volume = {18},
number = {3},
pages = {2489--2506},
doi = {10.62347/abom6140}
}
EUVIMED